undamentalytics Newsletter
Sign in

Gossamer Bio, Inc. balance sheet

At the end of fiscal 2025, Gossamer Bio, Inc. had total assets of $172m, total liabilities of $295m and shareholders' equity of −$123m. It held $37.7m in cash against $0 of debt: net cash of $37.7m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents11232463841
Receivables—05126
Total current assets26230731016873
Total assets27231231517277
Accounts payable16266
Deferred revenue (current)—017207
Total current liabilities49524563138
Short-term debt12120——
Long-term debt1210——
Total debt24120036
Total liabilities260249286295171
Shareholders' equity126329−123−94
Net debt (negative = net cash)−88−20−46−38−5
Shares outstanding94m—227m234m—

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: GOSS vs SIGAGOSS vs TNGXGOSS vs OCULGOSS vs NKTR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Gossamer Bio, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Gossamer Bio, Inc.